(R)-Crizotinib
(R)-Crizotinib (CAS 877399-52-5) is an ATP-competitive, orally bioavailable inhibitor targeting c-Met kinase, with a reported Ki of 4 nM. It inhibits phosphorylation of wild-type c-Met in various endothelial and tumor cell lines at an IC50 of approximately 11 nM. In cell-based assays, the compound reduces proliferation and induces apoptosis in GTL-16 gastric cancer cells, inhibits hepatocyte growth factor (HGF)-mediated migration and invasion of human NCI-H441 lung cancer cells, and suppresses cell scattering growth. (R)-Crizotinib demonstrates tumor growth inhibition efficacy across diverse xenograft models, including gastric, lung, renal, glioblastoma, and prostate cancers, highlighting its utility in oncology research.
References:
[1] Zou HY1, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL,Mroczkowski B, Christensen JG. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007 May 1;67(9):4408-17.
- 1. Irit Shapira-Netanelov, Olga Furman, et al. "Patient-Derived Gastric Cancer Assembloid Model Integrating Matched Tumor Organoids and Stromal Cell Subpopulations." Cancers (Basel). 2025 Jul 9;17(14):2287 PMID: 40723172
- 2. Lev A, Deihimi S, et al."Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer." Cancer Biol Ther. 2017 Sep 2;18(9):694-704. PMID: 28886275
- 3. Huang XX, Xie FF, et al. "Crizotinib synergizes with cisplatin in preclinical models of ovarian cancer." Am J Transl Res. 2017 Apr 15;9(4):1667-1679. PMID: 28469773
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 450.34 |
| Cas No. | 877399-52-5 |
| Formula | C21H22Cl2FN5O |
| Synonyms | Crizotinib,PF-2341066, PF02341066, PF 2341066 |
| Solubility | insoluble in H2O; insoluble in EtOH; ≥7.51 mg/mL in DMSO |
| Chemical Name | 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine |
| SDF | Download SDF |
| Canonical SMILES | C[C@H](c(c(Cl)c(cc1)F)c1Cl)Oc1c(N)ncc(-c2c[n](C3CCNCC3)nc2)c1 |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
|
Cell lines |
LLC SP and MP cell lines |
|
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
|
Reaction Conditions |
12 h; IC50=21.3 nM (MP cells); cell survival rate of 50.0±0.6%=22.4 nM (SP cells) |
|
Applications |
The inhibitory effects of crizotinib on MP cells and SP cells were determined by colony formation assay. The IC50 value of crizotinib for MP cells was 21.3 nM. Of note, the SP cells showed no significant changes after crizotinib treatment. However, the SP cells showed a cell survival rate of 50.0±0.6% following a combined treatment of crizotinib (22.4 nM) and verapamil (500 µM), compared with 105.3±0.4% survival of SP cells treated with crizotinib (22.4 nM) alone. The growth curves obtained demonstrate that crizotinib inhibited the growth of SP and MP cells, and this inhibition was dependent on both concentration and time. |
| Animal experiment [1]: | |
|
Animal models |
NU/NU nude mice |
|
Dosage form |
intratumoral injection |
|
Applications |
Tumorigenicity was examined using immune-deficient mice, into which SP or MP cells of LLC were subcutaneously transplanted. Nonsorted LLC cells formed xenografts in mice at 1x105 cells. Tumor size was significantly decreased in the crizotinib-treated LLC groups (225±29 mm3) compared to the untreated group (PBS: 834±41 mm3) by 40 days after treatment. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Xia P, Gou W F, Zhao S, et al. Crizotinib may be used in lewis lung carcinoma: A novel use for crizotinib[J]. Oncology reports, 2013, 30(1): 139-148. |
|
| Description | Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM, respectivley. | |||||
| Targets | c-Met | ALK | ||||
| IC50 | 11 nM | 24 nM | ||||
Quality Control & MSDS
- View current batch:
Chemical structure
Related Biological Data
Related Biological Data
Related Biological Data
